Gsk Share Discussion Threads

[imastu pidgitaswell] 23/3/2018 09:21

I would think there will be a transaction further down the line - but GSK now know who else is interested, and more importantly who is not.

Had to be the right thing to do, why overpay if you in a bidding process with, er no-one. Pfizer won't be too happy, but they overplayed their fairly weak hand - they'll be back trying to sell with a lower price envelope.

Added some more at 1285, but really wanted it to stay low once next year's pension contribution could be put to use after 6th April - maybe the wider market malaise will mean that I get to do that.

[nigelpm] 23/3/2018 09:17

The RNS implies GSK withdrew, rather than Pfizer turning the bid down. As EW said we wouldn't overpay and were right to take a look even if it came to nothing.

Suspect the reality as romeike notes is GSK did bid but Pfizer rejected, GSK were asked to try again and walked away.

Hopefully the business has gained some useful data from any due diligence to compensate for wasted management time.

[tradermichael] 23/3/2018 09:08

Only enhanced if the price goes back to before she opened her mouth.

[ygor705] 23/3/2018 09:05

Personally, I'm glad that the acquisition is not going ahead at this stage. There are plenty of other positive developments at GSK - the danger that all this good work was going to be masked by concerns about a large acquisition being made on a stretched-looking balance sheet. Timing is everything in this world and I believe that the CEO has made the correct call. Strangely, doing nothing may well have enhanced her reputation!

[tradermichael] 23/3/2018 08:21

Somehow, I'm not expecting the price to shoot back up to 1525p anytime soon ....... ;0)

[romeike] 23/3/2018 08:21

Clearly Pfizer didn't accept the original bod and wanted more, so GSK withdrew. Hopefully the share price can now get back on track. Not sure it's been worth the months of share price depression but good to have been able to pick up the cheap shares.

[dr biotech] 23/3/2018 08:13

The RNS implies GSK withdrew, rather than Pfizer turning the bid down. As EW said we wouldn't overpay and were right to take a look even if it came to nothing.

Shingrix approved in EU/Japan today - good news hidden under the other statement.

[tradermichael] 23/3/2018 08:10

GlaxoSmithKline plc (LSE/NYSE: GSK) today confirms it has withdrawn from the process relating to Pfizer's Consumer Healthcare business.
Emma Walmsley, Chief Executive Officer, GSK said:
"While we will continue to review opportunities that may accelerate our strategy, they must meet our criteria for returns and not compromise our priorities for capital allocation."

NOT A BINDING BID, THEN ????

[nigelpm] 23/3/2018 08:07

fairly muted reaction.

[montyhedge] 23/3/2018 08:04

Great news boys.

[nigelpm] 23/3/2018 08:02

As I suggested might happen yesterday ;-)

[davemac3] 23/3/2018 07:52

gsk withdraws from bidding for Pfizer CH, good or bad?

[zho] 23/3/2018 07:52

"GlaxoSmithKline plc (LSE/NYSE: GSK) today confirms it has withdrawn from the process relating to Pfizer's Consumer Healthcare business."

Good.

[abdullla] 23/3/2018 07:52

Wake up and smell the latest news !

[billionaire1] 22/3/2018 21:35

you are a genius

[abdullla] 22/3/2018 21:27

I told you so!

[buywell3] 22/3/2018 20:22

Chart here is now looking stressed like many of the posters

As the USA market drops to have a look at DJIA 22,500 IMO

1200 GSK seems likely again

Re Alzheimers' ... no cure exists

It will get renamed IMO a 'prion disease' within the next 2 years, as will some other dementia diseases

[philanderer] 22/3/2018 20:10

Opinion Lombard

'GSK’s pursuit of Pfizer consumer unit need not be a costly move'

A deal could give significant lift to earnings after three years

[essentialinvestor] 22/3/2018 16:57

PFZ deal may be a GSK/NVS combination as part of the JV, would not discount that.

[1fox1] 22/3/2018 16:49

Hmmmmmmmmmm Surpised £13 didn't hold. Not looking good. :o(

[fangorn2] 22/3/2018 16:33

Biggest concern would be overpaying for Pfizer Consumer unit and the getting PUT by Novartis shortly after.

Financially that'd be a disaster for GSK.

[romeike] 22/3/2018 16:04

You say awful job, but she hasn't really done anything for that to be a fair comment other than state the obvious that they would need to look at the Pfizer offering. The share price has been hit because of rampant negativity around what GSK might pay and how it would fund the aquisition.

If EW can get the brands at a low price it will be great for GSK with a big impact on EPS and huge scale in CH. But I think anything but a bargain buy will send the media into a tailspin over the dividend. GSK and Pfizer already teamed up on HIV - the suggestion they could do the same on consumer is an interesting option that I hope is being considered as it could offer the best of both worlds for both companies despite the initial complexities of getting it set up.

Personally I'd prefer Pfizer walk away and we can just get the share price back up to £16-17 and focus on the big pharma launches - so much positive things happening recently with no upside seen in the share price

Decided to add today.